Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
The von Hippel Lindau (VHL) gene has recently been identified as the genetic defect
resulting in a syndrome of multiple neoplasias. Patients with VHL disease develop retinal
angiomata, renal cysts and/or carcinomas, CNS hemangioblastomas as well as pancreatic cysts
and pheochromocytomas. Investigators have shown the gene to be a tumor suppressor type
proto-oncogene located at chromosomal locus 3p26. The gene includes three exons whose gene
product targets a cellular transcription factor Elongin SIII. Binding of the VHL proteins
to two subunits of this elongation factor inhibits transcription and may play a crucial role
in the clinical development of the von Hippel Lindau phenotype.
Observational
N/A
United States: Federal Government
970102
NCT00001668
April 1997
April 2000
Name | Location |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) | Bethesda, Maryland 20892 |